Delivery Order SPE2DB24D2012-SPE2DB25FBVDP

Award Date 1/27/25
Potential Completion Date 1/28/25
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,725.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of HAVRIX 1,440 UNIT/ML SYRINGEML, a medical vaccine product. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $3,761.11, is for the delivery of the vaccine product HAVRIX 1,440 UNIT/ML SYRINGEML. The contract is a firm-fixed price delivery order with a period of performance through November 5, 2024. The contract does not have a set-aside designation, indicating open competition....
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,100.22 firm fixed-price delivery order is for the supply of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product. The contract has an ultimate completion date of January 31, 2023 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,309.30, is for the procurement of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product. The award has an ultimate completion date of November 8, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award is between the Defense Logistics Agency (DLA) and AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,905.50, is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML. It is a firm fixed-price delivery order that runs through February 26, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order under a $999,999,999 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $33,489.76, is for the delivery of HAVRIX 1,440 unit/mL syringes. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds this IDC as a primary vehicle to provide a wide range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,389.95 fixed-price delivery order contract is for the supply of HAVRIX 1,440 UNIT/ML SYRINGE medical products, with a completion date of December 31, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award, valued at $30,871.52, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGE/ML, a medical product, with a period of performance through March 3, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,024.40, is for the delivery of HAVRIX 720 Unit/0.5 mL syringes, a vaccine product, to support medical requirements. The contract has a completion date of January 14, 2025 and is structured as a Firm Fixed Price Delivery Order. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,899.75 firm fixed-price delivery order is for the supply of HAVRIX 720 UNIT/0.5 ML SYRINGE 0.5ML, a vaccine product. The contract has an ultimate completion date of August 26, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
  • SPE2DB24D2012
    Indefinite Delivery Contract
  • SPE2DB24D2012-SPE2DB25FBVDP
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $1,157.28, is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML, a vaccine product. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

Generated 4/28/25, 9:51 AM